Overview

The development of mRNA as a therapeutic modality has fundamentally redefined modern vaccinology. Offering unprecedented speed, flexibility, and a high degree of tunability, mRNA vaccines leverage the host cell's own machinery to produce the target antigen in situ, resulting in robust and comprehensive immune activation. CD BioGlyco is an expert biology specialist, pioneering high-quality, end-to-end solutions for mRNA-based vaccine development. Our services are designed to navigate the complexities of design, synthesis, purification, and delivery, ensuring your vaccine candidate progresses rapidly from concept to clinic. We are committed to translating groundbreaking immunological science into clinically relevant, high-performing drug products.

Core Technologies

The success of any mRNA vaccine hinges on mastering two critical pillars: the integrity and translation efficiency of the mRNA molecule and the efficacy of the delivery system. We employ proprietary and industry-leading technologies to achieve superior product quality.

• Engineered mRNA Design and Modification
  Our platform utilizes advanced bioinformatics algorithms for complete sequence optimization, targeting maximal protein expression and minimal innate immune activation.
  • Codon optimization: Strategic substitution of synonymous codons to enhance translation speed and efficiency.
  • 5' Cap and poly(A) tail engineering: We ensure high capping efficiency (e.g., use of cap 1 analogs or enzymatic capping) for maximal translation initiation and precise poly(A) tail length control, critical for mRNA stability and longevity in the cytoplasm (Published Data).
  • Nucleoside modification: We specialize in incorporating modified nucleotides, such as N1-methyl-pseudouridine, which is proven to suppress the recognition of the mRNA by innate immune sensors (e.g., TLRs), significantly reducing immunogenicity while simultaneously boosting the stability and translational capacity of the mRNA molecule.
• Advanced Lipid Nanoparticle (LNP) Delivery Systems
  LNPs are the gold standard for mRNA delivery, protecting the fragile mRNA cargo from degradation by nucleases and facilitating effective entry into target cells via endocytosis. Our LNP platform leverages a defined mixture of:
  • Ionizable lipids: The core component, optimized to be positively charged at low pH for encapsulation and neutrally charged at physiological pH for safety, while promoting endosomal escape upon cellular uptake.
  • Structural lipids (phospholipids & cholesterol): Provide structural integrity and stability to the nanoparticle.
  • PEGylated lipids: Control the size and circulation time in vivo (pharmacokinetics).

Accelerating Immunotherapy: mRNA-based Vaccine Development

Vaccine development commences with antigen sequence design and optimization, including UTR and codon optimization, plus nucleoside modifications like m1Ψ to enhance expression. A high-quality DNA template is then prepared for the in vitro transcription (IVT) reaction, where mRNA is synthesized and capped. The crude mRNA is purified using chromatography and filtration to remove impurities such as DNA template, enzymes, and dsRNA. Subsequently, the mRNA is encapsulated into lipid nanoparticles (LNPs) via microfluidics, ensuring high encapsulation efficiency and stability, followed by sterile filtration. Finally, the product undergoes comprehensive analytical testing to confirm identity, purity, potency, and other critical quality attributes.

Workflow

Vaccines

Applications

• Research for Prophylactic Infectious Disease Vaccines

We partner with biopharma companies to design and optimize mRNA constructs targeting infectious diseases. Our research focuses on rapid antigen prototyping for seasonal pathogens (like influenza and RSV), emerging viruses, and neglected diseases, accelerating the early-stage development of vaccine candidates.

• Investigation in Oncology & Cancer Immunotherapy

Our services support the research of mRNA-based cancer vaccines. We conduct preclinical studies on vaccines encoding tumor-associated antigens (TAAs) and neoantigens, providing partners with data on eliciting targeted immune responses for both personalized and off-the-shelf immunotherapy approaches.

• Exploration of Protein Replacement & Therapeutic Modalities

We investigate the use of mRNA as a research tool for producing proteins in vivo. Our collaborative R&D efforts focus on modeling treatments for monogenic disorders, metabolic diseases, and other conditions where transient protein expression offers a potential research pathway.

• Development of Personalized & Combination Strategies

Our platform is utilized to research bespoke therapeutic solutions. We work with partners to develop and test patient-specific vaccine regimens and study combination strategies with other agents in a preclinical setting to evaluate potential synergistic effects.

• Applied Research in Veterinary Medicine & Livestock Health

We conduct applied research to adapt mRNA technology for animal health. This includes the design and testing of vaccines for companion animals and livestock, supporting partners in developing solutions for veterinary diseases and zoonosis control.

• R&D for Antibody & Immunomodulatory Applications

Our research includes pioneering novel approaches where mRNA encodes therapeutic antibodies or immunomodulators. We perform proof-of-concept studies for this "passive immunization from within" strategy, providing partners with early-stage research data.

Advantages

• Unrivaled Product Purity and Safety

We specialize in aggressively reducing critical impurities. Our rigorous downstream process ensures exceptionally low levels of dsRNA (Residual Double-Stranded RNA), which correlates directly with reduced reactogenicity and enhanced translational performance.

• Rapid, Integrated Design-to-Dose Cycle

Our integrated platform combines advanced sequence optimization and microfluidic LNP manufacturing under one quality system. This holistic approach dramatically shortens development timelines, allowing your program to move faster toward key milestones.

• Custom LNP & saRNA Flexibility

Beyond conventional mRNA, we offer tailored development of saRNA, which requires significantly lower doses due to its replication capability, maximizing therapeutic value. Our custom LNP library and formulation expertise ensure the best delivery vehicle for your specific application.

• Scalability and Robust Manufacturing

We have built a vertically integrated manufacturing platform designed for seamless scale-up from preclinical to commercial scales. Our processes are rigorously characterized and controlled, ensuring batch-to-batch consistency and reliable supply to meet your program's evolving demands.

• Proprietary Analytical and Bioanalytical Suite

Our investment in cutting-edge analytics goes beyond standard assays. We employ advanced techniques for deep structural characterization of mRNA and in-depth profiling of LNP critical quality attributes, providing you with an unparalleled level of product understanding.

• A Focus on Innovation and Platform Excellence

Our commitment extends to continuous platform improvement. We actively pioneer novel lipid chemistries and formulation strategies aimed at enhancing targeting efficiency and broadening the therapeutic window for next-generation applications.

Frequently Asked Questions

Customer Review

• CD BioGlyco' commitment to purity is unparalleled. The ultra-low dsRNA levels in their mRNA significantly reduced off-target inflammation in our preclinical models, allowing us to accurately assess the true efficacy of our novel vaccine candidate. Their structural characterization data was flawless.

— Dr. Li, Principal Investigator, Vaccine Research Laboratory

• The speed of the integrated service—from design to encapsulated LNP—was truly impressive. They hit our aggressive timeline for the IND-enabling studies. Their responsiveness and expertise in LNP customization were key to our program's success.

— Manager Chen, Program Director, Infectious Disease Therapeutics

• We valued the expert consultation on our saRNA design. The team at CD BioGlyco helped us fine-tune the replicon for maximal in vivo expression, resulting in a robust, dose-sparing cancer vaccine candidate. Highly recommend their sequence optimization service.

— Scientist K., Senior Research Scientist, Oncology Development Group

Associated Services

While our mRNA-based vaccine development service focuses on cutting-edge nucleic acid platforms, we recognize the continued importance of traditional vaccine approaches. For conjugate vaccine development, our One-stop Solutions for Polysaccharide Conjugation provide comprehensive support encompassing Carrier Protein design, Polysaccharide Antigen Production, and advanced Conjugation Technologies to create effective glycoconjugate vaccines.

CD BioGlyco offers an unparalleled, integrated mRNA-based vaccine development service, underpinned by expert knowledge, advanced LNP technology, and a commitment to delivering superior product purity and comprehensive analytical data. Contact us to advance the next generation of vaccines and nucleic acid therapies.